MX2023012759A - Composiciones anti-siglec y usos de las mismas. - Google Patents

Composiciones anti-siglec y usos de las mismas.

Info

Publication number
MX2023012759A
MX2023012759A MX2023012759A MX2023012759A MX2023012759A MX 2023012759 A MX2023012759 A MX 2023012759A MX 2023012759 A MX2023012759 A MX 2023012759A MX 2023012759 A MX2023012759 A MX 2023012759A MX 2023012759 A MX2023012759 A MX 2023012759A
Authority
MX
Mexico
Prior art keywords
siglec
compositions
antibodies
disclosure relates
cancer therapy
Prior art date
Application number
MX2023012759A
Other languages
English (en)
Spanish (es)
Inventor
Yang Liu
Pan Zheng
Mingyue Liu
Martin Devenport
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of MX2023012759A publication Critical patent/MX2023012759A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023012759A 2021-04-30 2022-04-29 Composiciones anti-siglec y usos de las mismas. MX2023012759A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182271P 2021-04-30 2021-04-30
PCT/US2022/027006 WO2022232558A1 (en) 2021-04-30 2022-04-29 Anti-siglec compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012759A true MX2023012759A (es) 2023-11-13

Family

ID=83848703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012759A MX2023012759A (es) 2021-04-30 2022-04-29 Composiciones anti-siglec y usos de las mismas.

Country Status (10)

Country Link
US (1) US20240218067A1 (enExample)
EP (1) EP4329806A4 (enExample)
JP (1) JP2024515879A (enExample)
KR (1) KR20240006519A (enExample)
CN (1) CN117355331A (enExample)
AU (1) AU2022267362A1 (enExample)
CA (1) CA3216324A1 (enExample)
IL (1) IL308137A (enExample)
MX (1) MX2023012759A (enExample)
WO (1) WO2022232558A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643575B (zh) * 2023-11-03 2026-04-24 中山大学 一种纳米材料及其制备方法和应用
WO2026055671A1 (en) * 2024-09-09 2026-03-12 OncoC4, Inc. Anti-siglec compositions and uses thereof for treating neurodegenerative diseases
CN120459278A (zh) * 2025-07-14 2025-08-12 南京医科大学 Siglec-10/G或包含Siglec-10/G蛋白结构的融合蛋白在制备治疗胶质瘤药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171114A1 (en) * 2008-04-11 2012-07-05 Haeuw Jean-Francois Anti-cd151 antibodies and their use in the treatment of cancer
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
WO2015107171A1 (en) * 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody
AU2016354924A1 (en) * 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer

Also Published As

Publication number Publication date
AU2022267362A1 (en) 2023-11-09
IL308137A (en) 2023-12-01
JP2024515879A (ja) 2024-04-10
EP4329806A1 (en) 2024-03-06
WO2022232558A1 (en) 2022-11-03
CA3216324A1 (en) 2022-11-03
US20240218067A1 (en) 2024-07-04
EP4329806A4 (en) 2025-09-17
TW202305005A (zh) 2023-02-01
AU2022267362A9 (en) 2023-11-16
CN117355331A (zh) 2024-01-05
KR20240006519A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2020013169A (es) Conjugados de camptotecina.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
CL2021002769A1 (es) Anticuerpos de unión a vista (divisional solicitud n° 201902610)
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
MX2020008772A (es) Conjugados de il-15, y sus usos.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
DOP2023000150A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
PE20220750A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
BR112022000876A2 (pt) Anticorpos imunomoduladores e métodos de uso destes
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
PY2018313A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
CO2018000414A2 (es) Inmunoconjugados de il22
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
SA523450167B1 (ar) أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
CL2023001269A1 (es) Construcción polipeptídica que se une a cd3; composiciòn farmacéutica; y su uso.